💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Oseltamivir

CHEMBL1229 Phase 4 승인됨 Small molecule
Half-Life
6-10 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
312.4 g/mol
LogP
1.1
Phase
4

An antiviral neuraminidase inhibitor for treating and preventing influenza, most effective within 48 hours.

분자량

312.4050 g/mol

LogP

1.10

TPSA

90.70 Ų

리핀스키 5의 법칙

통과

치료 영역

Respiratory Disease Pain Management Asthma Chronic Obstructive Pulmonary Disease Insomnia Gastroesophageal Reflux Disease Systemic Lupus Erythematosus Obesity Hypertension Chronic Pain Heart Failure

약물 분류

J — J - Antiinfectives for Systemic Use

작용 기전

Neuraminidase inhibitor preventing viral release from host cells.

Pharmacokinetics (PK)

Half-Life 6-10 hours

Pharmacodynamics (PD)

기전

Neuraminidase inhibitor preventing viral release from host cells.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H28N2O4

                    

                    
                    

                        
HBD / HBA

                        
2 / 5

                    

                    
                    

                        
회전 가능 결합

                        
8

                    

                    
                    
                    

                        
무거운 원자

                        
22

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Oseltamivir + Warfarin
                            
                        

                        
                        
Oseltamivir does not appear to meaningfully alter warfarin pharmacokinetics; however, the febrile illness being treated may independently elevate INR, which can be mistakenly attributed to the antiviral.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Oseltamivir + Methotrexate
                            
                        

                        
                        
Both oseltamivir carboxylate and methotrexate rely on renal tubular secretion via OAT transporters; theoretically, competition could reduce elimination of either drug, though clinical evidence of a significant interaction is limited.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
An antiviral neuraminidase inhibitor for treating and preventing influenza, most effective within 48 hours.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Neuraminidase inhibitor preventing viral release from host cells.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Oseltamivir: Half-life: 6-10 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Oseltamivir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Amoxicillin
                            Small molecule
                        
                        
                        
                            Azithromycin
                            Small molecule
                        
                        
                        
                            Ciprofloxacin
                            Small molecule
                        
                        
                        
                            Doxycycline
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1229.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 65028.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.